Get the Daily Brief
Latest Biotech News
Areteia winds down after late‑stage asthma terminations
Areteia Therapeutics is winding down after terminating its Phase 3 asthma studies, the company said via sources. Executives have exited and development activity is being halted, ending one of the...
Milestone wins FDA approval: nasal spray for PSVT cleared
Milestone Pharmaceuticals secured FDA approval for Cardamyst (etripamil), a nasally administered treatment for paroxysmal supraventricular tachycardia (PSVT), after earlier regulatory setbacks....
Palvella posts positive Phase 2 for rapamycin gel in pediatric skin disease
Palvella Therapeutics said its 3.9% topical rapamycin gel produced clinical improvements in a mid-stage trial for a rare pediatric skin disease, reporting positive Phase 2 data. The company...
Sobi buys Arthrosi: $950m upfront to lock in Phase‑3 gout asset
Sobi agreed to acquire Arthrosi Therapeutics for $950 million in cash with up to $550 million in milestones, securing pozdeutinurad (AR882), a Phase‑3 URAT1 inhibitor for progressive gout. The...
Argenx halts Vyvgart Hytrulo trials: interim review finds low chance of success
Argenx reported that an independent data monitoring committee recommended stopping late‑stage trials of Vyvgart Hytrulo in thyroid eye disease after an interim analysis concluded the studies were...
Sanofi’s BTK candidate fails Phase 3 – regulatory timeline slips
Sanofi disclosed that its BTK inhibitor tolebrutinib failed Phase‑3 trials in multiple sclerosis after missing endpoints in two different disease forms, prompting the company to reassess...
Chai Discovery raises $130m Series B... valuation at $1.3bn
Chai Discovery closed a $130 million Series B round at a $1.3 billion valuation, extending the rapid funding trajectory of the AI‑driven biotech founded in 2024. The financing was led by growth...
Child death after brain‑directed gene therapy: Capsida trial under scrutiny
A report in STAT detailed the sudden death of a child two and a half days after receiving an experimental brain‑directed gene therapy, triggering concern across academic and commercial...
Structure’s oral GLP‑1 soars — Phase II weight loss fuels 100% stock rally
Structure Therapeutics reported positive Phase II ACCESS results for aleniglipron, an oral GLP‑1 candidate, triggering a >100% jump in its share price. The company disclosed placebo‑adjusted...
Laguna Bio bets engineered Listeria on pediatric leukemia: living drug nears clinic
Laguna Bio unveiled a therapeutic strategy that engineers a highly attenuated Listeria monocytogenes strain to activate multifaceted immune responses—targeting gamma delta T cells—and announced...
Fertility gene PRDM9 helps glioblastoma resist chemo — blocking it clears persisters
Researchers at the University of Sydney reported that glioblastoma persister cells co‑opt the fertility gene PRDM9 to produce cholesterol that enables survival during chemotherapy. The Nature...
Open‑source platform speeds drug‑combination discovery: cell‑level screening unveiled
Researchers published an open‑source screening platform in Nature Communications that accelerates identification of synergistic drug combinations across cellular models. The platform integrates...
Keep neutrophils in night mode: ATI2341 reduces post‑MI inflammation in models
A team from CNIC and Yale reported in Journal of Experimental Medicine that neutrophils follow a circadian program that alters their aggressiveness, making nighttime neutrophils less damaging...
Child dies after experimental brain gene therapy — field confronts safety alarm
A young child died two and a half days after receiving an experimental viral vector designed to deliver genes deep into the brain, according to a STAT+ report. The patient had been treated with a...
Sobi to buy Arthrosi for $950M upfront — gout pipeline deal locks in late‑stage asset
Swedish drugmaker Sobi agreed to acquire Arthrosi Therapeutics, paying $950 million upfront plus up to $550 million in milestone payments, the company announced. Arthrosi’s lead candidate is a...
Structure’s oral GLP‑1 posts double‑digit weight loss — shares surge after Phase II readout
Structure Therapeutics reported positive Phase II data for aleniglipron, an oral, biased GPCR agonist for obesity, showing a placebo‑adjusted mean weight loss in the low double digits at 36 weeks...
FDA clears Milestone’s nasal arrhythmia spray — Cardamyst approved after two rejections
The FDA approved Milestone Pharmaceuticals’ nasally delivered emergency treatment Cardamyst (etripamil) for a form of cardiac arrhythmia, the company confirmed. Cardamyst had been turned down...
Laguna Bio advances engineered Listeria living drug — pediatric leukemia trial planned
Laguna Bio is advancing a living‑therapeutic approach that uses a highly attenuated Listeria monocytogenes strain engineered to activate multifactorial immune responses, the founders told...
AI and physics model find Parkinson’s candidate — Gain Therapeutics announces mechanism‑based lead
Gain Therapeutics disclosed a drug discovered through an AI plus physics‑based modeling platform that allosterically binds a dysfunctional enzyme, restores its function, and reduces...
Human monoclonal antibodies neutralize clade 2.3.4.4b H5N1 — Nature Communications report
Researchers reported new human monoclonal antibodies that potently neutralize clade 2.3.4.4b H5N1 hemagglutinin, according to a Nature Communications paper. The antibodies show broad binding and...